CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin
← catalyst calendarSponsored by DexCom, Inc. (industry) · DXCM — their whole pipeline →. With Jaeb Center for Health Research, Scripps Research Digital Trial Center, Precision Data Health, Inc..
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
283actual
Sites
21
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-15 | actual | When the study began enrolling |
| Primary completion | 2026-05-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-16 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes
Intervention
- Device: CGM
Primary outcome
what the primary-completion date above is the date OFTo assess the benefit on glycemic control and safety from baseline to week 26 using CGM versus RC.
measured 26 weeks
Permalink · DXCM's whole pipeline · Catalyst calendar · Every registered study · What changed